Vildagliptin Supplier Information and Product Details

Synonyms: NVP-LAF-237, (2S)-1-[(3-Hydroxytricyclo[3.3.1.1³,⁷]dec-1-yl)amino]acetyl-pyrrolidine-2-carbonitrile, 2-Pyrrolidinecarbonitrile, 1-[(3-hydroxytricyclo[3.3.1.1³,⁷]dec-1-yl)amino]acetyl-, (2S)-, Galvus, Laf-237, Unii-I6B4B2U96p, Vidagliptin

Product Categories: Galvus, Other APIs, Amines, Chiral Reagents, Heterocycles, Intermediates, Fine Chemicals, Pharmaceuticals, Isotope Labelled Compounds, Metabolites, Impurities, API, Inhibitor

Frequently Asked Questions about Vildagliptin

Q: What is Vildagliptin used for?

A: Vildagliptin is primarily used for the treatment of type 2 diabetes mellitus. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors.

Q: How does Vildagliptin work?

A: Vildagliptin works by inhibiting the DPP-4 enzyme, which leads to increased levels of incretin hormones. This results in improved insulin secretion and decreased glucagon secretion, helping to control blood sugar levels in diabetic patients.

Q: What are the common adverse reactions of Vildagliptin?

A: Common adverse reactions may include headache, dizziness, nausea, and hypoglycemia. However, the specific adverse reactions can vary, and patients should consult their healthcare provider for a complete list of potential side effects.

Q: Is Vildagliptin available as a generic medication?

A: Yes, Vildagliptin is available as a generic medication in many countries. It's also marketed under the brand name Galvus by Novartis Pharmaceuticals.